In addition, in Europe, these guidelines include a search for BRCA1/2 tumor mutations because they are European Medicines Agency-approved targets for treatment with olaparib for ovarian cancer patients with platinum-sensitive relapse [12]. The gene discussed is BRCA1; the disease is ovarian cancer.